Definitive Contract HHSO100201600029C
Award Date
9/1/16
Potential Completion Date
7/1/24
Potential Value
$81M
Awardee
Modernatx, Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Cambridge, MA 02139, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $1,754,345,480.45 definitive cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Moderna, Inc. for the development of an mRNA vaccine to licensure for the prevention of COVID-19. The contract includes pre-award costs, development of the mRNA vaccine to Biologics License Application (BLA), and domestic manufacturing scale-out. This award does not have a set-aside designation. Moderna, a for-profit pharmaceutical...
This definitive contract was awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Moderna US, Inc. for COVID-19 vaccinations in support of the 2022 Fall Vaccine Campaign. The $7.8 billion firm fixed price contract is a transfer from the original awarding agency, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, and represents continuation of vaccine production...
This is a $335,333,551.74 definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Takeda Vaccines Inc. for the development of a Zika virus vaccine. The contract has a period of performance through September 30, 2024. It is a cost-plus-fixed-fee contract with no set-aside designation. The contract supports ASPR's Zika virus research and vaccine development initiatives. As the prime contractor, Takeda Vaccines Inc. is leading the effort and...
This is a definitive contract awarded by the Joint Program Executive Office for Chemical and Biological Defense, a Defense Department agency, to Moderna, Inc. for 100 million doses of the SARS-CoV-2 mRNA-1273 vaccine. The $8.2 billion firm fixed price contract has an ultimate completion date of August 10, 2023. Moderna, a manufacturer of pharmaceutical goods, has previously received prime and subcontract awards from various government agencies including the Department of Veterans Affairs,...
This is a $163,807,201.00 cost-plus-fixed-fee definitive contract awarded to Sanofi Pasteur Inc. by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) for the development of an inactivated Zika virus vaccine. The contract has a performance period ending on July 15, 2022 and was awarded on October 1, 2016. Sanofi Pasteur Inc. is a large pharmaceutical manufacturer that has been awarded multiple indefinite...
This is a $7,239,392.55 cost-plus-fixed-fee delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) to Emergent Manufacturing Operations Baltimore LLC. The order is for the development and manufacturing of a whole virion inactivated Zika virus vaccine under the Centers for Innovation in Advanced Development and Manufacturing (CIADM) program, with a performance period through December 23,...
This federal contract award to Modernatx, Inc. is for the Deployable Accelerated RNA Technology (DART) program, managed by the Defense Advanced Research Projects Agency (DARPA). The $51,494,206.00 other transaction agreement is for the development of advanced messenger RNA (mRNA) technologies to rapidly produce therapeutic proteins or antibodies. The award aims to accelerate the development of COVID-19 countermeasures, as Modernatx has previously supported DARPA, the Department of Veterans...
<p>The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense (DOD - Army - USASC) awarded a Definitive Contract valued at $7,837,399,999.00 to Moderna US, Inc. Moderna US Inc. Division for COVID-19 MRNA Vaccines. The place of performance will be in Cambridge, MA 02139, USA and the period of performance is from July 28, 2022 through March 31, 2023. The pricing structure is Firm Fixed Price.</p>
This is a $9,800 firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, to Protein Sciences Corporation. The contract is for the provision of Zika-tested proteins, with a period of performance ending on June 17, 2016. Protein Sciences Corporation is a for-profit manufacturer that has received multiple federal contracts from NIAID and the Office of the Assistant Secretary for...
The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, has awarded a $408,692.00 firm fixed price contract to Univercells SA for research and development on mRNA vaccine production using the company's NFINITYtm platform. The contract, awarded on September 30, 2023, has a completion date of May 31, 2025 and is not set aside for any specific business type. This contract falls under the agency's vaccine development programs, aiming to...